---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Photobiomodulation"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Photobiomodulation. Topics: FDA De Novo authorization: indications for use, Treatment regimen, LIGHTSITE III: best-corrected visual acuity in the FDA review, LIGHTSITE III: new-onset and existing geographic atrophy at Month 13, and 1 further topic. 5 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/photobiomodulation"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Photobiomodulation

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Photobiomodulation

<a id="topic-2.2.2.1.2-1"></a>

### FDA De Novo authorization: indications for use

> “The Valeda Light Delivery System is intended to provide improved visual acuity in patients with best-corrected visual acuity of 20/32 through 20/70 and who have dry age-related macular degeneration (AMD) characterized by:”
> “The presence of at least 3 medium drusen (> 63 µm and ≤ 125 µm in diameter), or large drusen (> 125 µm in diameter), or non-central geographic atrophy, AND”
> “The absence of neovascular maculopathy or center-involving geographic atrophy.”
> “Safety and effectiveness in patient populations and/or conditions excluded from the clinical study has not been established.”

Source: [FDA De Novo DEN230083 (2024)](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN230083.pdf)

<a id="topic-2.2.2.1.2-2"></a>

### Treatment regimen

> “Each treatment takes a total of 250 seconds and consists of four phases as described below.”
> “For each treatment series, the patient receives 3 treatments each week for a total of 9 treatments over a period of 3-5 weeks.”

Source: [FDA De Novo DEN230083 (2024)](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN230083.pdf)

> “Subjects were given multiwavelength PBM (590, 660, and 850 nm) or Sham treatment delivered in a series of nine sessions over 3 to 5 weeks every four months over 24 months.”

Source: [Boyer et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10885856/)

<a id="topic-2.2.2.1.2-3"></a>

### LIGHTSITE III: best-corrected visual acuity in the FDA review

> “Using multiple imputation analysis with the mITT dataset (PBM: n = 91, Sham: n = 54), the study met the predetermined primary effectiveness BCVA endpoint at Month 21 with the following results.”
> “At Month 13: The mean PBM result was 2.6 letters better than the mean Sham result (p=0.0548; non-significant);”
> “At Month 21: The mean PBM result was 3.8 letters better than the mean Sham result (p=0.0036; significant).”
> “In terms of the primary effectiveness endpoint (difference between study arms in terms of mean BCVA change from baseline), the device demonstrated a statistically significant improvement which is of marginal clinical significance.”
> “The effect of treatment with the device past 2 years and the duration of treatment effect is also unknown at this time.”

Source: [FDA De Novo DEN230083 (2024)](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN230083.pdf)

<a id="topic-2.2.2.1.2-4"></a>

### LIGHTSITE III: new-onset and existing geographic atrophy at Month 13

> “A very small number of eyes presented with noncenter involving GA at baseline (PBM, n = 6; Sham, n = 5).”
> “Using FAF analysis, a numerical trend showed an increase in GA lesion area in Sham (1.48, SE 0.94; SD 1.62) compared with PBM-treated eyes (1.16, SE 0.66; SD 1.32, P = 0.75) at Month 13 (change from baseline; Table 2; Figure 5).”
> “The occurrence of new GA was significantly higher in the Sham versus PBM group (P = 0.024, Fisher exact test, odds ratio 9.4) (Table 2; Figure 5).”

Source: [Boyer et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10885856/)

<a id="topic-2.2.2.1.2-5"></a>

### Guideline appraisal and evidence grade

> “LIGHTSITE I and II and a Cochrane review in 2021 did not show a benefit of photobiomodulation”
> “but a follow-up study, LIGHTSITE III in 2024, showed that photobiomodulation appears to decrease the onset of new GA”
> “I-, Insufficient quality”
> “In 2024, the U.S. Food and Drug Administration (FDA) approved a device for multiwavelength photobiomodulation”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
